Ever Supreme Bio Technology Co., Ltd (TPEX:6712)
Taiwan · Delayed Price · Currency is TWD 146.50
-1.00 (-0.68%)
Aug 19, 2026, 1:30 PM CST
TPEX:6712 Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 15,011 | 14,366 | 14,158 | 14,338 | 15,025 | 13,013 | |
Market Cap Growth | 10.91% | 1.47% | -1.25% | -4.57% | 15.46% | 32.03% |
Enterprise Value | 14,186 | 14,053 | 13,525 | 13,324 | 13,889 | 11,764 |
Last Close Price | 147.50 | 152.38 | 143.85 | 141.35 | 143.57 | 121.48 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 30.13 | 33.45 | 38.55 | 26.58 | 74.86 | 35.21 |
Forward PE | 31.74 | 28.18 | 42.17 | 41.07 | 44.55 | - |
PS Ratio | 13.88 | 14.12 | 15.16 | 18.91 | 23.94 | 29.65 |
PB Ratio | 5.34 | 9.41 | 7.89 | 7.78 | 8.38 | 6.86 |
P/TBV Ratio | 8.75 | 9.49 | 7.94 | 7.83 | 8.44 | 6.90 |
P/FCF Ratio | 23.80 | 26.85 | 32.51 | 34.47 | 47.55 | 97.33 |
P/OCF Ratio | 23.77 | 26.79 | 32.15 | 34.00 | 47.07 | 95.90 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 13.12 | 13.81 | 14.48 | 17.57 | 22.13 | 26.81 |
EV/EBITDA Ratio | 28.41 | 31.17 | 30.72 | 37.25 | 45.20 | 83.16 |
EV/EBIT Ratio | 29.73 | 32.01 | 32.11 | 39.45 | 48.94 | 101.24 |
EV/FCF Ratio | 22.49 | 26.26 | 31.06 | 32.04 | 43.95 | 87.99 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.08 | 0.03 | 0.00 | 0.00 | 0.01 | 0.02 |
Debt / EBITDA Ratio | 0.47 | 0.08 | 0.01 | 0.02 | 0.06 | 0.23 |
Debt / FCF Ratio | 0.37 | 0.07 | 0.01 | 0.01 | 0.06 | 0.26 |
Net Debt / Equity Ratio | -0.29 | -0.26 | -0.52 | -0.72 | -0.70 | -0.69 |
Net Debt / EBITDA Ratio | -1.69 | -0.88 | -2.12 | -3.72 | -4.07 | -9.26 |
Net Debt / FCF Ratio | -1.31 | -0.74 | -2.15 | -3.20 | -3.96 | -9.79 |
Asset Turnover | 0.42 | 0.49 | 0.44 | 0.38 | 0.31 | 0.31 |
Inventory Turnover | 3.21 | 3.80 | 3.67 | 3.48 | 2.94 | 4.19 |
Quick Ratio | 1.76 | 1.59 | 3.46 | 6.20 | 8.28 | 14.58 |
Current Ratio | 1.89 | 1.78 | 3.72 | 6.57 | 8.89 | 15.20 |
Return on Equity (ROE) | 23.35% | 25.86% | 20.19% | 29.68% | 10.88% | 27.60% |
Return on Assets (ROA) | 11.47% | 13.25% | 12.50% | 10.42% | 8.88% | 5.04% |
Return on Invested Capital (ROIC) | 21.08% | 36.16% | 48.91% | 55.47% | 38.21% | 21.70% |
Return on Capital Employed (ROCE) | 16.70% | 27.80% | 23.30% | 18.30% | 15.70% | 6.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.15% | 2.99% | 2.59% | 3.76% | 1.34% | 2.84% |
FCF Yield | 4.20% | 3.72% | 3.08% | 2.90% | 2.10% | 1.03% |
Dividend Yield | 2.24% | 2.19% | 3.01% | 3.34% | 1.00% | 2.68% |
Payout Ratio | 71.67% | 94.96% | 119.82% | 25.27% | 154.19% | - |
Buyback Yield / Dilution | -4.01% | 0.92% | 1.68% | 1.01% | -0.15% | -11.01% |
Total Shareholder Return | -1.77% | 3.10% | 4.68% | 4.35% | 0.85% | -8.33% |